Cyclin-dependent kinases (CDKs), a family of serine/ threonine kinases, are responsible for coordinating the events by which cells progress through the cell cycle and become active at specific phases: G1, S, G2, and M. [1] [2] [3] [4] [5] [6] In the G1 phase, cyclin D1 increases to trigger the activation of CDK4/6 in early G1, and then cyclin E/CDK2 is activated. CDK4/6 activities are negatively regulated by the tumor suppressor p16, a cyclin-dependent kinase inhibitor of the INK4 family. However, many tumors have been reported to contain mutations, deletions, or silencing of p16.
Cyclin-dependent kinases (CDKs), a family of serine/ threonine kinases, are responsible for coordinating the events by which cells progress through the cell cycle and become active at specific phases: G1, S, G2, and M. [1] [2] [3] [4] [5] [6] In the G1 phase, cyclin D1 increases to trigger the activation of CDK4/6 in early G1, and then cyclin E/CDK2 is activated. CDK4/6 activities are negatively regulated by the tumor suppressor p16, a cyclin-dependent kinase inhibitor of the INK4 family. However, many tumors have been reported to contain mutations, deletions, or silencing of p16. [7] [8] [9] Moreover, mutations in CDKs and abnormal expressions of their regulators have been found in a large percentage of melanoma patients. 10) In addition, Malumbres and Barbacid have reported that knockdown of CDK4 in mammary tumor cells prevents tumor formation, 11) and McCormick and Tetsu have found that cancer cells proliferate despite CDK2 inhibition. 12) These results suggest that selective inhibition of CDK4 may restore normal cell activity and could be a more valuable approach to cancer therapy than CDK2, especially for those who have lost the INK4 family such as p16.
In our previous paper, we reported the discovery of the potent CDK4 (IC 50 ϭ0.038 mg/ml) inhibitor (1), which had moderate selectivity for CDK2 with strong cytotoxic activity 13, 14) (Fig. 1) . The cell cycle distribution analysis in HTC116 cells was carried out with selected compounds, same as 1, and the DNA content of the cells was assessed by flow cytometry. After treating the cells with the compounds, significant increases in G0/G1 population were observed. Furthermore, apoptosis was induced in some compounds, which is indicated by the sub-G1 fraction. However, during our studies to improve selectivity and the physical profile of 1, we found that thieno [2,3-d] pyrimidine hydrazones with a phenyl ring had a common feature of poor chemical stability under acidic conditions. Since we aimed to investigate orally available drugs, we had to prevent the degradation of compounds by gastric acid. Therefore, we tried to change the electronic environment around the hydrazone moiety by introducing heteroaryl groups such as imidazoles, oxazoles, and thiazoles instead of the phenyl ring. We found that thiazole compounds were well tolerated in the acidic condition and they also possessed potent CDK4 inhibitory activity. To further explore the potential of this class of compounds, we introduced various substituted thiazole at the hydrazone moiety and the alkyl group at the C-6 position of thieno [2,3-d] pyrimidine scaffold.
Herein, we report the chemical stabilities of compound 1, and describe the design, synthesis of novel analogues of 1,3-thiazole-2-carbaldehyde thieno [2,3-d] pyrimidin-4-yl hydrazone with marked enhancement of chemical stability, and their inhibitory activities for CDK4 with selectivity against CDK2. We also report their cytotoxic potential against human cancer cell lines.
Chemistry and Chemical Stability Preparation of 1 and 4a-n was accomplished using a general synthetic route as shown in Chart 1. The hydrazone analogues 4a-n were produced by a condensation reaction with 2 and appropriate aldehydes 3a-n in benzene, followed by deprotection in the case of 4d, 4e, and 4g-n.
In our recent studies, the chemical stability of compound 1 was examined in pH 1 37°C , and the corresponding remaining ratios are given in Fig. 2 . Compound 1 is reasonably stable in neutral solution, but a rapid decrease of 1 was observed in acidic conditions. We then evaluated the acidic hydrolysis of 1 by HPLC analysis. As a result, an inverse correlation was observed between the production of hydrazine 2 and the decomposition of 1. In order to overcome this problem, we tried to change the electronic environment around the hydrazone moiety by introducing heteroaryl groups (R 1 ) as imidazoles, oxazoles, and thiazoles instead of a benzene ring. We found that a series of compounds 4a-c, bearing a non-substituted thiazole group, was well tolerated in the acidic condition and they also possessed potent CDK4 inhibitory activity as shown in Table 1 . Among these compounds, 1,3-thiazole-2-yl compound 4a showed excellent CDK4 inhibitory activity with some selectivity against CDK2 (4.9-fold). In contrast, 1,3-thiazole-5-yl compound 4c had poor selectivity. The plot of the remaining ratio of compound 4a in pH 1.2 is shown in Fig. 2 , with no data in pH 6.8 because 4a was insoluble under the condition. From these results, we selected 4a to initiate our study to improve CDK4/CDK2 selectivity and cytotoxicity for further investigation.
The synthesis of aldehydes was described as follows. The thiazole aldehydes 3a-c were commercially available. The substituted thiazole aldehydes 3d-f were prepared using the reported method of Dority Jr. et al. 15) as shown in Chart 2. After bromination of 5a, b and amination with methylamine, followed by N-Boc protection, 6a, b were produced, respectively. 6a was converted to aldehyde 3d with n-BuLi and Nformylmorpholine. Aldehydes 3e and 3f were obtained from 6b and commercial dimethylamine 6c in the same manner. Aldehyde 3g was prepared from 7. Thiazole 7 was synthesized using the reported method of Subhash et al. 16) After reduction of ethyl ester using lithium aluminum hydride (LAH), Mitsunobu reaction was carried out to introduce the amino methyl unit at the C-4 position. Deprotection of the phthalimide group of 8 with hydrazine monohydrate gave the corresponding amine, followed by protection with the Boc group. After deprotection of the tert-butyldiphenylsilyl (TBDPS) group with tetrabutylammonium fluoride (TBAF), oxidation of the resulting alcohol with MnO 2 afforded aldehyde 3g.
The substituted thiazole aldehydes 3h-j were synthesized as shown in Chart 3. As reported by Illig et al., 17) 11a was obtained from commercially available compound 9a using the reaction of thioamide 10 16) and bromomethyl ketone intermediate, which was made by diazoketone and hydrogen bromide. After the protection of amine 13 with phthalic anhydride, 11b was synthesized from 9b in a similar manner. 12a, b were obtained from 11a, b by the procedure for 3g. 12c was prepared from 12a by deprotection of N-Boc and methylation of resulting amine, followed by N-Boc protection. Conversion of 12a-c to 3h-j was carried out by the procedure utilized for the preparation of 3g. The substituted thiazole aldehydes 3k-n, containing a cyclic alkyl group or fused ring, were synthesized as shown in Chart 4. 15a-c were obtained from 14a-c in a similar manner to 11a, respectively. N-Cbz deprotection of 15a-c followed by N-Boc protection afforded 16a-c. Finally, 16a-c were converted to 3k-m by the procedure for 3h. Bicyclic compound 3n was synthesized from thioamide 17 and pyrrolidin-3-one 18. After a-bromination of 18 and cyclization with 17, dehydration was performed by treatment with methanesulfonyl chloride, followed by deprotection of O-benzyl and N-Ts with HBr, and then N-Boc protection afforded 19. Conversion to aldehyde 3n from 19 was performed as previously described.
The hydrazine 21 was prepared from 20 with hydrazine monohydrate in ethanol under reflux. The thiophenes 23a-f were synthesized from appropriate alcohols 22a-f with methyl cyanoacetate in the presence of sulfur by the method of Tinney et al. 18) 27 was obtained from 25 and 26 via 2,2-dimethyl-4-pentenal, 19) followed by reduction of aldehyde, and protection of hydroxide with TBDPSCl. Thiophene 23g was synthesized in the same manner as 23a-f after LemieuxJohnson oxidation of 27. Cyclization of 23a-g with formamide gave 4-oxothieno [2,3-d] pyrimidines. The hydrazines 24a-h were prepared from chlorination of 4-oxothieno [2,3-d] pyrimidines with phosphorus oxychloride, followed by treatment with hydrazine monohydrate according to the reported procedure. 20) For hydrazine 24h, intermediate 28 was fluorinated with (dimethylamino)sulfur trifluoride after removal of TBDPS protection. The hydrazone analogues 29-38 were produced by a condensation reaction with hydrazines 21, 24a-h, and aldehyde 3d or 3h in benzene, followed by deprotection (Chart 5).
Biological Evaluation Biological activities of the novel thieno [2,3-d] pyrimidin-4-yl hydrazone analogues were evaluated in two assay systems: enzyme inhibitory activity against CDK4/CDK2 and cytotoxicity against two cell lines 994
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Previously, we reported that the presence of an ionizable nitrogen atom at the C-4Ј position on the benzene plays an important role in the cytotoxic activity.
14) Therefore, we introduced a series of substituent groups with alkyl amine at the C-4Ј or C-5Ј position on the thiazole ring. All the derivatives in Table 2 maintained fairly good CDK4 inhibitory activity and chemical stability. 4-[(Methylamino)methyl]-1,3-thiazole-2-yl compound 4d and 5-[(methylamino)methyl]-1,3-thiazole-2-yl compound 4e sustained good CDK4 activity as 4a, and 4d had improved selectivity (28.8-fold vs. CDK2). On the other hand, 4e was less selective. Therefore, we undertook replacements with a variety of alkyl amine analogues at the C-4Ј position. Primary amine compound 4g diminished cytotoxic activity and selectivity against CDK2. In contrast, tertiary amine compound 4f exhibited similar IC 50 values for 4d. Then we noted the steric factors around a nitrogen atom of alkyl amine. Among the branched alkyl amines 4h-j, compound 4h improved its CDK4 inhibitory activity with good selectivity (43.7-fold vs. CDK2), and 4h exhibited an IC 50 value of 0.103 mg/ml against PC-6 cells. Conversely, we found that cyclic alkyl amino groups, as exemplified by compounds 4k-n, markedly decreased cytotoxic activities. These results showed that the presence of the substituent alkyl amino group at the C-4Ј position of the thiazole ring is very important and its steric factor influences cytotoxic activity.
For further improvement of cytotoxic activity, our effort was then focused on determining the effect of the alkyl group at the C-6 position. The biological activity and chemical stability data for 29-38 are shown in Table 3 . Branched alkyl derivatives 29, 31-35 maintained potent CDK4 inhibitory activity with selectivity (15.2 to 46.7-fold vs. CDK2). Among these analogues, compounds 32 and 35 had moderately good cytotoxicity against HCT116 and PC-6 (IC 50 range: 0.108 to 0.315 mg/ml) with sufficient chemical stability. Meanwhile, cyclic alkyl compounds 30, 31, and 33 were less potent in cytotoxic activity. Next, we assessed the branched alkyl derivatives containing a heteroatom at the C-6 position. Hydroxyl compound 36 retained CDK4 inhibitory activity, but reduced cytotoxic activity. By contrast, hydrophobic fluorinated analogue 37 improved cytotoxic activities with weaker activity of CDK4 inhibition than that of 36. Moreover, 38 had potent kinase inhibitory activity, and cytotoxic activity was nearly equivalent to that of 1. These results suggest that modification of side chains at the C-6 position probably plays a crucial role for the improvement of pharma- (Fig. 3) .
Conclusion
In summary, we achieved the conversion into thiazole from the phenyl ring at the heteroaryl moiety of the C-4 hydrazone with adequate chemical stability. Next, we will focus on the optimization of the thiazole ring at the hydrazone and the C-6 position of the thieno[2,3-d]pyrimidine moiety. Also, compounds 4h, 32, 35, and 38 have been identified as potent, selective CDK4 inhibitors with marked chemical stability and cytotoxic activity. Moreover, 35 showed efficacy in a xenograft model of the HCT116 cells. These results provide valuable information for the design of a potent CDK4 inhibitor and they also hold great promise for cancer therapy. We plan to evaluate the medical safety and pharmacokinetics using 35 for more optimization of this analogue, and further work will be reported elsewhere on the improvement of cytotoxic activity, CDK4 selectivity, and the physical profile in due course.
Experimental
Chemical Stability Assay For the chemical stability assay in aqueous solution, a 1 ml aliquot of 0.5 mg/ml stock solution of substrate in MeOH was added to 50 ml of the appropriate buffer solution. The prepared solution was incubated at 37°C in the dark. At regular intervals, samples of the solution were analyzed by HPLC using the following conditions: a Waters Xterra RP18, 2.1 mmϫ10 cm, 3.5 mm column; mobile phase, 25 mM pH 6.8 phosphate buffer/acetonitrileϭ65/35; flow rate 0.3 ml/min; detector wavelength, 210 nm and 340 nm. Samples were also analyzed by LC-MS using the following conditions: (LC) a Waters Xterra RP18, 2.1 mmϫ5 cm, 3.5 mm column; mobile phase, 10 mM pH 6.8 sodium acetate-acetic acid buffer/acetonitrileϭ60/40; flow rate 0.4 ml/min; detector wavelength, 340 nm; (MS) a ThermoQuest LC-Q; ionization condition, Electron spray ionization (ESI); scanning method, positive scan (M.W. 100-400).
Chemistry Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. The solvent and reagent names are abbreviated as follows: H-NMR spectra were recorded on a JEOL JNM EX400, and chemical shifts are given in ppm (d) from tetramethylsilane as an internal standard. Significant 1 H-NMR data are tabulated in the following order: number of protons, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), coupling constant(s) in hertz. Infrared (IR) spectra were recorded on a Hitachi 270-30 spectrometer and a JASCO FT/IR-6100. Electron spray ionization condition (ESI) mass spectra were recorded on an Agilent 1100 and SCIEX API-150EX spectrometer. Fast atom bombardment ionization condition (FAB) mass spectra were recorded on a JEOL JMS-HX110 spectrometer. Electron impact ionization condition (EI) mass spectra were recorded on a JEOL JMS-AX505W. High-resolution mass spectra were obtained on a JEOL JMS-100LP AccuTOF LC-plus spectrometer (ESI) or a JEOL JMS-700 mass spectrometer (EI). Elemental analysis was performed using a PerkinElmer CHNS/O 2400II or a Yokokawa Analysis IC7000RS, and analytical results were within Ϯ0.4% of the theoretical values unless otherwise noted. tert-Butyl Methyl(1,3-thiazol-4-ylmethyl)carbamate (6a) To a solution of 4-methyl-1,3-thiazole 5a (3.0 g, 30.25 mmol) in CCl 4 (60 ml) were added N-bromosuccinimide (5.6 g, 31.77 mmol) and 2,2Ј-azobisisobutyronitrile (250 mg, 1.51 mmol, 5 mol%). The reaction mixture was refluxed for 30 min under an atmosphere of nitrogen and cooled to room temperature. The resulting white precipitate was filtered. The filtrate was diluted with THF and partially evaporated to afford crude 4-bromomethyl-1,3-thiazole as a THF solution, which was used in the next step without purification. Methylamine (2 m THF solution, 45 ml, 90.75 mmol) was added successively to the THF (15 ml) solution of 4-(bromomethyl)thiazole. The resulting mixture was stirred for 18 h at room temperature. After completion of the reaction, the insoluble matter was filtered off and the filtrate was evaporated. The residue was dissolved in THF (60 ml) and the solution was cooled to 0°C. Boc 2 O (6.9 ml, 30.25 mmol) and Et 3 N (4.6 ml, 33.28 mmol) were added. The solution was allowed to warm to room temperature and stirred for 5 h. The resulting precipitate was filtered. The filtrate was concentrated under reduced pressure, and the residue was chromatographed on silica gel eluted 996
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Fig. 3. Tumor Growth Inhibition Curves of 35
with n-hexane/EtOAc (3 : 1) to afford title compound 6a (2. tert-Butyl [(2-Formyl-1,3-thiazol-4-yl)methyl]methylcarbamate (3d) To a solution of n-butyllithium (1.52 m in n-hexane, 3.02 ml, 4.60 mmol) in Et 2 O (10 ml) under an atmosphere of argon at Ϫ78°C was added dropwise a solution of 6a (1.0 g, 4.38 mmol) in Et 2 O (10 ml). The mixture was stirred at Ϫ78°C for 1 h, and then 4-formylmorpholine (462 ml, 4.60 mmol) was added. The mixture was stirred for 1 h at Ϫ78°C, and then at Ϫ5°C overnight. The reaction mixture was then separated with satd NaHCO 3 aq. and EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (4 : 1) to afford title compound 3d (392.7 mg, 35%) as a yellow oil. 
2-{[2-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-1,3-thiazol-4-yl]methyl}-1H-isoindole-1,3(2H)-dione (8)
To a solution of ethyl 2-(tert-butyldiphenylsilyloxymethyl)thiazole-4-carboxylate 7 (748.3 mg, 1.76 mmol) in THF (14 ml) was added LAH (67 mg, 1.76 mmol) at 0°C, and stirred at room temperature for 5 h. After cooling at 0°C, MeOH (0.2 ml), water (0.1 ml), 15% NaOH aq. (0.1 ml), and water (0.3 ml) were added to a reaction mixture successively. The precipitate was filtered through Celite. The filtrate was concentrated under reduced pressure and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (2 : 1-1 : 1). The eluate was concentrated under reduced pressure and the residue was dissolved in THF (20 ml Formyl-1,3 -thiazol-5-yl)carbamate (3g) To a solution of 8 (441.9 mg, 0.86 mmol) in EtOH (4.4 ml) was added hydrazine monohydrate (0.95 ml, 1.89 mmol) at room temperature. After 2 h, Boc 2 O (0.65 ml, 2.84 mmol), CH 2 Cl 2 (4.4 ml), and satd NaHCO 3 aq. (4.4 ml) were added to the reaction mixture, and stirred for a further 2 h. The solution was partitioned between CH 2 Cl 2 and water. The aqueous layer was washed several times with CH 2 Cl 2 and the combined organic fractions were dried over Na 2 SO 4 . The reaction mixture was concentrated under reduced pressure and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc
To a solution of the afforded compound (181.1 mg, 0.38 mmol) in THF (1.8 ml) was added TBAF (1 M THF solution, 0.37 ml, 0.37 mmol) at 0°C, and stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure, and the residue was chromatographed on silica gel eluted with CHCl 3 /MeOH (20 : 1). The eluate was concentrated under reduced pressure and the residue was dissolved in CCl 4 (1.0 ml). To this solution was added MnO 2 (160 mg) and stirred under reflux for 4.5 h. The reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure to afford title compound 3g (41.3 mg, 20%) as a yellow oil. 
2-{1-[2-(Hydroxymethyl)-4,5-dihydro-1,3-thiazol-4-yl]ethyl}-1H-isoindole-1,3(2H)-dione (11a)
A mixture of N-phtahloyl-DL-alanine 9a (2.19 g, 10 mmol), a catalytic amount of DMF (2 drops) and thionyl chloride (1.09 ml, 15 mmol), was stirred under reflux for 30 min and cooled to room temperature. The solvent was removed under reduced pressure. The residue was dissolved in THF (10 ml), and (trimethylsilyl)diazomethane (2 M nhexane solution, 12.5 ml, 25 mmol) in THF (25 ml) was added at 0°C. The reaction mixture was stirred at 0°C for 18 h. After removal of the solvent under reduced pressure, the residue was separated with satd NaHCO 3 aq. and Et 2 O. The aqueous layer was extracted with Et 2 O and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (2 : 1) to afford 1-diazo-3-phthalimidobutan-2-one (2.35 g, 97%) as an orange oil. To the resulting oil (0.49 g, 2.0 mmol) in Et 2 O (20 ml) was added hydrobromic acid (47%, 0.28 ml, 2.4 mmol) at 0°C, and stirred at room temperature for 50 min. The reaction mixture was neutralized with NaHCO 3 aq, the aqueous layer was extracted with Et 2 O, and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was dissolved in EtOH (20 ml). To this solution was added 2-{[tertbutyl(diphenyl)silyl]oxy}ethanethioamide 10 (0.66 g, 2.0 mmol), and the reaction mixture was stirred under reflux for 12 h. After removal of the solvent under reduced pressure, the residue was separated with water and EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (2 : 3) to afford title compound 11a (0.4 g, 69%) as an orange oil. 1 
2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)butanoic Acid (9b)
A mixture of 2-aminobutyric acid 13 (10.3 g, 100 mmol) and phthalic anhydride (14.8 g, 100 mmol) was heated at 120°C for 4 h. After cooling to room temperature, CHCl 3 (50 ml) and 1 N HCl aq. (50 ml) were added to the reaction mixture. The aqueous layer was extracted with CHCl 3 and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure to afford title compound 9b (23 g, 99%) as a colorless oil. 1 ml, 29.1 mmol) and TFAA (2.1 ml, 14.5 mmol) at 0°C, and stirred at room temperature for 1 h. The reaction mixture was then separated with 10% citric acid aq. The aqueous layer was extracted with CH 2 Cl 2 and the combined organic layer was washed with satd NaHCO 3 aq. and brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was dissolved in DMF (20 ml). To this solution, K 2 CO 3 (1.9 g, 13.7 mmol) and methyl iodide (0.43 ml, 6.9 mmol) were added, and the reaction mixture was stirred overnight at room temperature. The reaction mixture was separated with EtOAc and 10% sodium hydrosulfite aq. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with water and brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was dissolved in THF (10 ml) and 1 N NaOH aq. (10 ml 
Benzyl 3-[2-(Hydroxymethyl)-1,3-thiazol-4-yl]azetidine-1-carboxylate (15a)
A mixture of 1-benzyloxycarbonylazetidine-3-carboxylic acid 14a (1.2 g, 5.0 mmol), a catalytic amount of DMF (2 drops), and oxalyl chloride (0.63 ml, 7.5 mmol), was stirred at 0°C for 15 min and then stirred at room temperature for 1 h. The solvent was removed under reduced pressure. The residue was dissolved in THF (30 ml), and (trimethylsilyl)diazomethane (2 M n-hexane solution, 6.25 ml, 12.5 mmol) was added at 0°C. The reaction mixture was stirred at 0°C for 15 h. After removal of the solvent under reduced pressure, the residue was separated with satd NaHCO 3 aq. and EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure. To the resulting residue in Et 2 O (20 ml) was added hydrobromic acid (47%, 0.7 ml, 6.0 mmol) at 0°C, and stirred at 0°C for 1 h. The reaction mixture was neutralized with NaHCO 3 aq., the aqueous layer was extracted with EtOAc, and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was dissolved in EtOH (30 ml). To this solution was added 2-{[tert-butyl(diphenyl)silyl]oxy}ethanethioamide 10 (1.65 g, 5.0 mmol), and the reaction mixture was stirred under reflux for 38 h. After removal of the solvent under reduced pressure, the residue was separated with water and EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (1 : 2) to afford title compound 15a (0.4 g, 26%) as a brownish oil. 97 mmol) in THF (10 ml) and 1 N NaOH aq. (10 ml), and stirred at room temperature for 30 min. To the reaction mixture EtOAc and water were added, and the two layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with CHCl 3 /MeOH (40 : 1) to afford title compound 16a (40 mg, 11%) as a brownish oil. 45 (9H, s), 3.21 (1H, br), 3.85-3.91 (1H, m) 
tert-Butyl 3-(2-Formyl-1,3-thiazol-4-yl)pyrrolidine-1-carboxylate (3l)
Compound 3l was obtained from 16b as a yellow oil (83%) by following the procedure described for 3k. tert-Butyl 4-(2-Formyl-1,3-thiazol-4-yl)piperidine-1-carboxylate (3m) Compound 3m was obtained from 16c as an orange oil (60%) by following the procedure described for 3k. 1 3-one 18 (1.4 g, 5 .86 mmol) in AcOH (15 ml) was added bromine (0.33 ml, 6.4 mmol) in AcOH (15 ml). The mixture was stirred at 50°C for 10 min. The reaction mixture was separated with water and CHCl 3 . The aqueous layer was extracted with CHCl 3 and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was dissolved with DMF (15 ml). To this solution was added 2-(benzyloxy)ethanethioamide 17 (1.2 g, 6.6 mmol), and the reaction mixture was stirred at 50°C for 7 h under N 2 atmosphere. After completion of the reaction, NaHCO 3 (0.5 g, 5.86 mmol) was added, and the solvent was removed under reduced pressure. To the residue, EtOAc and water were added, and the two layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was dissolved in CH 2 Cl 2 (50 ml). To this solution were added Et 3 N (4.1 ml, 29.3 mmol) and MsCl (0.91 ml, 11.7 mmol) at 0°C under N 2 atmosphere, and stirred at room temperature for 22 h. To the reaction mixture, CHCl 3 and water were added, and the two layers were separated. The aqueous layer was extracted with CHCl 3 and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with CHCl 3 /MeOH (100 : 1). The eluate was concentrated under reduced pressure. To the resulting residue were added phenol (2.0 g) and hydrobromic acid (47%, 3.0 ml) at 0°C, and stirred under reflux for 1 h. After cooling to ambient temperature, Et 2 O and water were added to the reaction mixture. The two layers were separated, and the organic layer was extracted with 1 N HCl aq. The combined aqueous layer was alkalized with 10 N NaOH aq. To the basic solution, Boc 2 O (0.55 g, 2.5 mmol) in THF (20 ml) was added, and stirred at room temperature for 23 h. To the reaction mixture, EtOAc and water were added, and the two layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with CHCl 3 /MeOH (50 : 1) to afford title compound 19 (0.13 g, 9%) as a brownish solid. 
4-Hydrazino-6-isopropylthieno[2,3-d]pyrimidine (21)
To a solution of 20 (13.8 g, 64.9 mmol) in EtOH (250 ml) was added hydrazine monohydrate (140 ml). The mixture was stirred under reflux for 3 h and cooled to room temperature. The precipitate was collected by filtration and washed with n-hexane to afford title compound 21 (12.9 g, 95%) as a pale yellow solid. Methyl 2-Amino-5-cyclopropylthiophene-3-carboxylate (23a) To a suspension of pyridinium chlorochromate (7.50 g, 34.8 mmol) in CH 2 Cl 2 (50 ml) was added 2-cyclopropylethanol 22a (2.0 g, 23.2 mmol), and stirred vigorously at room temperature under N 2 atmosphere. After 1.5 h of stirring, Et 2 O (180 ml) was added and stirred for 30 min. The reaction mixture passed through a Florisil ® column to afford cyclopropylacetaldehyde (1.59 g) as a colorless oil. The resulting aldehyde was added to a solution of methyl cyanoacetate (1.50 ml, 17 mmol), Et 3 N (2.40 ml, 17 mmol), and DMF (2.65 ml, 34 mmol) under N 2 atmosphere. After 10 min of stirring, S 8 (545 mg, 17 mmol) was added and stirred at room temperature for 40 h. The reaction mixture was poured into water and extracted with EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with nhexane/EtOAc (9 : 1) and recrystallized from n-pentane to afford title compound 23a (580 mg, 13%) as a pale yellow solid. 
6-Cyclopropyl-4-hydrazinothieno[2,3-d]pyrimidine (24a)
A mixture of 23a (550 mg, 2.79 mmol) in formamide (5.5 ml) was stirred at 210°C for 2.5 h. After cooling, precipitate formed, which was separated from the solution by filtration and washed with water. The crude product was chromatographed on silica gel eluted with n-hexane/EtOAc (2 : 1) and recrystallized from EtOAc and n-hexane to afford 6-cyclopropylthieno[2,3-d]pyrimidin-4(3H)-one (285 mg, 53%) as a colorless solid. The resulting compound (255 mg, 1.32 mmol) in phosphorous oxychloride (3.0 ml) was stirred at 110°C for 6 h. The reaction mixture was concentrated under reduced pressure. The residue was poured into ice water, and sat. NaHCO 3 aq. was added and extracted with EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (9 : 1) to afford 4-chloro-6-cyclopropylthieno[2,3-d]pyrimidine (275 mg, 99%) as a colorless solid. To a solution of the resulting compound (250 mg, 1.18 mmol) in EtOH (5.0 ml) was added hydrazine monohydrate (2.5 ml). The mixture was stirred under reflux for 1.5 h and cooled to room temperature. The reaction mixture was concentrated under reduced pressure. After EtOAc and water were added, the two layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was recrystallized from EtOAc and n-hexane to afford title compound 24a (190 mg, 78%) as a colorless solid. Methyl 2-Amino-5-cyclobutylthiophene-3-carboxylate (23b) Compound 23b was obtained from 22b as a pale yellow oil (37%) by following the procedure described for 23a. (1H, s), 8.54 (1H, s), 8.61 (1H, br), 9.33 (2H, br) Methyl 2-Amino-5-(1-methylpropyl)thiophene-3-carboxylate (23c) Compound 23c was obtained from 22c as a pale yellow oil (36%) by following the procedure described for 23a. Methyl 2-Amino-5-cyclohexylthiophene-3-carboxylate (23e) Compound 23e was obtained from 22e as a yellow oil (5%) by following the procedure described for 23a. tert-Butyl[(2,2-dimethylpent-4-en-1-yl)oxy]diphenylsilane (27) To a mixture of isobutyraldehyde 25 (25 ml, 0.275 mol) and allyl alcohol 26 (12.5 ml, 0.183 mol) in p-cymene (40 ml) was added p-TsOH (60 mg) and stirred under reflux for 24 h. Distillation gave 2,2-dimethyl-4-pentenal (14.8 g, 72%) as a colorless oil. To a suspension of LAH (0.8 g, 21 mmol) in Et 2 O (60 ml) was added dropwise 2,2-dimethyl-4-pentenal (8.00 g, 71 mmol) in Et 2 O (40 ml) at room temperature, and stirred under reflux for 3 h. After cooling to 0°C, MeOH (1.8 ml), water (0.8 ml), 15% NaOH aq. (0.8 ml), and water (2.4 ml) were added to the reaction mixture successively. The precipitate was filtered through Celite. The filtrate was concentrated under reduced pressure and the residue was purified by vacuum distillation to afford 2,2-dimethyl-4-pentenol (5.9 g, 73%) as a colorless oil. To a solution of pentenol (2.28 g, 20 mmol) in THF (50 ml) were added imidazole (1.50 g, 22 mmol) and TBDPSCl (5.7 ml, 22 mmol). The reaction mixture was stirred at room temperature for 20 h. After EtOAc and water were added, the two layers were separated. The organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (50 : 1) to afford title compound 27 (5.05 g, 72%) as a colorless oil. 2 mmol) in a mixture of THF (140 ml) and H 2 O (70 ml) were slowly added OsO 4 (180 mg, 5 mol%) and NaIO 4 (6.10 g, 28.5 mmol), and the mixture was stirred at 50°C for 2 h. Et 2 O and sat. Na 2 S 2 O 3 aq. were added to the reaction mixture, and the two layers were separated. The aqueous layer was extracted with Et 2 O and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (20 : 1) to afford 4-{[tert-butyl(diphenyl)silyl]oxy}-3,3-dimethylbutanal (2.50 g, 50%) as a colorless oil. The resulting aldehyde was added to a solution of methyl cyanoacetate (0.65 ml, 7.5 mmol), Et 3 N (1.05 ml, 7.5 mmol), and DMF (1.1 ml, 14 mmol) under N 2 atmosphere. After 3 min of stirring, S 8 (225 mg, 7.0 mmol) was added and stirred at room temperature for 72 h. The reaction mixture was poured into water and extracted with EtOAc. The aqueous layer was extracted with EtOAc and the combined organic layer was washed with brine and dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (9 : 1) to afford title compound 23g (2.50 g, 76%) as a pale yellow oil. 
4-[(Methylamino)methyl]-1,3-thiazole-2-carbaldehyde [6-(2-Hydroxy-1,1-dimethylethyl)thieno[2,3-d]pyrimidin-4-yl]hydrazone (36)
A mixture of 24g (885.6 mg, 1.86 mmol) and 3d (500 mg, 1.95 mmol) in benzene (17 ml) was stirred under reflux for 3 h and cooled to room temperature. The reaction mixture was concentrated under reduced pressure. The residue was chromatographed on silica gel eluted with n-hexane/EtOAc (2 : 1) to afford crude hydrazone (777 mg). To a solution of the hydrazone in THF (8 ml) was added TBAF (1 M THF solution, 1.3 ml, 1.31 mmol) at 0°C, and stirred at 75°C for 15 h. The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with n-hexane/EtOAc (1 : 3) to afford crude hydroxide (35.8 mg). To a solution of the hydroxide in 1,4-dioxane (1.5 ml) was added 4 N HCl in 1,4-dioxane (1.5 ml) at 0°C. The mixture was stirred at room temperature for 16 h and concentrated under reduced pressure. The residue was recrystallized from EtOH, EtOAc, and nhexane to afford title compound 36 (9.3 mg, 2%) as a yellow solid. 4 mmol) in THF (100 ml) was added TBAF (1 M THF solution, 36.7 ml, 36.7 mmol) at 0°C, and stirred overnight at 70°C. After cooling, CHCl 3 and brine were added, and the two layers were separated. The organic layer was dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with CHCl 3 /MeOH (100 : 3). The eluate was concentrated under reduced pressure, and the residue was recrystallized from CHCl 3 and EtOAc to afford 6-(1,1-dimethyl-2-hydroxyethyl)thieno [2,3-d] pyrimidin-4-one (2.01 g, 49%) as a brownish solid. To a solution of afforded compound (1.60 g, 7.14 mmol) in CH 2 Cl 2 (240 ml) was added (dimethylamino)sulfur trifluoride (3.77 ml, 28.6 mmol) at Ϫ78°C and warmed to room temperature over 2 h with stirring. The reaction mixture was neutralized with a solution of sat NaHCO 3 , and the two layers were separated. The organic layer was dried over Na 2 SO 4 . The solvent was removed under reduced pressure, and the residue was chromatographed on silica gel eluted with CHCl 3 /MeOH (100 : 1) to afford 6-(2-fluoro-1,1-dimethylethyl)thieno [2,3- Kinase Inhibition Assay CDK4, CDK2, cyclin D, and cyclin E proteins were purified from baculovirus-infected Sf-9 insect cells. Glutathione Stransferase Rb (GST-Rb) protein was expressed and purified from bacteria using glutathione-sepharose beads as per standard procedure. Enzyme assays to determine the concentration of compounds that cause 50% of kinase inhibition (IC 50 ) were performed in 96-well filter plates (Whatmann, GF/C filter). The assay mixture (30 ml of 10 mM ATP contained 0.2 mCi [ 33 P]ATP, 30 ml of enzymes (Cdk4/D1 or Cdk2/E), 30 ml of 25% GST-Rb with glutathione sepharose beads in kinase assay buffer (50 mM Hepes pH 7.4, 10 mM MgCl 2 , 1 mM DTT, 2.5 mM EGTA, 5 mg/ml AMSF, 5 mg/ml aprotinine, 0.1 mM NaF, 10 ml b-glycerophosphate, and 0.1 mM sodium-o-vanadate) and 10 ml of the tested compound in a final volume of 100 ml) was incubated on the plate for 30 min at 30°C. The plate was washed four times and the kinase activities were measured. The IC 50 values were determined by analyzing the dose-response inhibition curves.
Cytotoxicity Assay An 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was performed against HCT116 and PC-6 cell lines to examine the growth inhibitory effects of our compounds. HCT116 cell line was purchased from American Type Culture Collection (ATCC, U.S.A.). PC-6 cell line was obtained from Immuno-Biological Laboratories (Gunma, Japan). The cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. The cells were plated in 96-well micro plates on Day 0, and stock solutions serially diluted in DMSO were added to each well on Day 1. After 3 d of culture (Day 4), the number of viable cells was determined by the MTT assay. The concentration of compounds that cause 50% of growth inhibition was calculated by the following equation: 100ϫ[(TϪT 0 )/(CϪT 0 )]ϭ50 (C: control optical density; T: test optical density; T 0 : optical density at time zero).
Cell Cycle Distribution Analysis HCT116 cells were treated with test compounds for 16 h and were stained with propidium iodide using a Cycle Test Kit (Becton Dickinson). Then the cells were analyzed using a FACscan flow cytometer with CellQuest software (Becton Dickinson) in accordance with the manufacturer's recommendations. The percentage of cells in the G0/G1, S, and G2/M phases of the cell cycle were quantified using Modifit software (Verity Software House, Inc.).
Antitumor Activity Assay For in vivo studies, HCT116 tumor cells were subcutaneously transplanted into the right hind limb of male BALB/cnu/nu mice (Japan SLC, Inc.), aged 5 or 6 weeks. After the subcutaneous tumors averaged 80-100 mm 3 in size, the tested compounds dissolved in 20% Captisol ® (b-cyclodextrin sulfobutylether sodium salt, CyDex, Inc.) solution were administered intravenously or orally once a day for 4-6 d at the doses. The tumor volume was measured with a caliper periodically.
